Upcoming Events
Search Result For "Drugdiscovery".
- Event Type
- Event Category
- Event Country
- Event Date
Event Type
Categories
Country
City
Date
One of the most pivotal gatherings of your industry peers is happening soon and now's the time to get ahead of your competitors. CPHI Middle East i...
As innovative drug delivery platforms beyond GalNac continue to emerge and novel chemical modifications are discovered, the potential for RNAi ther...
Making Strides in Targeting PARP, ATR, ATM, WEE1 and POLθ AstraZeneca and Merck are at the forefront of DDR inhibitor development, focusing on ...
Proteomics offers huge advantages for the discovery and pre-clinical development of small molecule drugs and their translation into robust clinical...
The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolster...
Welcome to the 4th Novel Conjugates Summit! We are witnessing a surging 83% growth of novel drug conjugates, with major collaborations between N...
The rapid therapeutic success of PROTACs and Molecular Glue Degraders has underpinned a surge in new proximity-based modalities with the ability to...
With clinical momentum from Eli Lilly's lipidated brain shuttle siRNAs, Alnylam Pharmaceuticals' ALN-APP siRNA, Wave's Phase 1b/2a positive SELECT-...
Welcome to the 3rd CRISPR-Based Therapy Analytical Development Summit Spearheading Regulatory Compliance of Genome Editing Therapies The 3rd CR...
2025 marks an exciting phase for covalent drugs, with the field doubling down on de-risked assets and tackling high-value targets in oncology, i...
Discover, Develop and Selectively Deliver Highly Stable and Potent RNAi Therapeutics for Targeted and Effective Gene Silencing in Oncology, Rare...
With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to ...
Loading More...
